⚕ GalenOps CRO console
← SITE015 (POL)

SITE015-0422

withdrawn
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE015 (POL) (Dr. Ito) · consented 2023-07-31
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 9); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 15); relationship: N

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-08 (study day 20); relationship: Y

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-13 (study day 25); relationship: N

moderate assessed 2026-08-18

Grade 2 Diarrhoea — outcome: UNKNOWN; onset 2023-10-12 (study day 54); relationship: Y

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 75); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 75); relationship: N

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 75); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.